Abstract: Disclosed are methods and means for facilitating injection which enable a correct penetration depth of the needle.

Abstract: The present invention is in the area of administration forms and delivery systems for drugs, vaccines and other biologically active agents. More specifically the invention is related to the preparation of suspensions of colloidal solid lipid particles (SLPs) of predominantly anisometrical shape with the lipid matrix being in a stable polymorphic modification and of suspensions of micron and submicron particles of bioactive agents (PBAs); as well as to the use of such suspensions or the lyophilizates thereof as delivery systems primarily for the parenteral administration of preferably poorly water-soluble bioactive substances, particularly drugs, and to their use in cosmetic, food and agricultural products. SLPs and PBAs are prepared by the following emulsification process: (1) A solid lipid or bioactive agent or a mixture of solid lipids or bioactive agents is melted.

Abstract: The invention relates to freeze-dried soft, flexible and continous matrix of low-molecular weight hyaluronic acid or salt thereof, in which the molecular weight of the hyaluronic acid is preferably between 50 000 and 200 000 Da, containing at least one peptide or protein. It also relates to a pharmaceutical composition in the form of a layer which is characterised by this freeze-dried low-molecular weight hyaluronic acid containing at least one peptide or protein. The drug is preferably chosen from at least one of GH, IGF-I, IGF-II and/or EGF and could be mixtured with an antibiotic agent. The process for the manufacture of this matrix and the use of the pharmaceutical composition for the manufacturing of a drug for wound healing is claimed. The invention discloses a method for accurately obtaining a predetermined dosage of a topically administerable drug which is characterised by freeze-drying a water solution of low-molecular weight hyaluronic acid and the peptide or protein to form a layer.

Abstract: Staphylococcal enterotoxins obtained by secretion from Staphylococcus aureus, by expression of enterotoxins in other bacteria or cells, or by chemical mutagenic treatment of Staphlococcus aureus strains are used in treatment of cancer as tumoricidal agents. Enterotoxins A, B, C, D, E and toxic shock toxin (TSST-1) can be administered via simple intravenous injection or in the form of adjuvants such as pluronic triblock copolymers. Enterotoxins may also be used ex-vivo to induce mitogenesis, enlarge and enrich a tumoricidal T-cell population. Streptococcus pyrogenic exotoxins which have structural and functional homology to the enterotoxins, are also useful in tumoricidal treatment. Chemically derivatized enterotoxins as well as synthetic or genetically prepared polypeptides having structural homology to the native enterotoxins are also useful in this application.

Abstract: Supercapsulated strains of group A and C streptococci are provided. The strains are used in the production of hyaluronic acid with a molecular weight exceeding 6 million.

Abstract: Disclosed are methods and means for facilitating injection which enable a correct penetration depth of the needle.

Abstract: A process for the manufacture of sustained release pellets comprising pelletizing a mixture containing the drug in finely divided form and a binder. The characteristic feature is that:(a) said binder is in particle form consisting of one or more water-insoluble wax-like binder substance(s) with a melting point above 40.degree. C., and(b) said pelletization step is performed by mechanically working said mixture, in a high shear mixer, under the input of a sufficient amount of energy for the binder to melt and pelletization to take place.

Abstract: The use of a quinoline-3-carboxamide compound comprising structure (I), optionally with substituents for the hydrogen atoms shown (H.sup.1-9), and a salt of compound (I) where (a) ---- represents that there are two conjugated double bonds between the atoms comprised by the dashed line, (b) X.sub.1 and X.sub.2 are separately selected form an oxygen atom or an NH.sup.9 group, said X.sub.1 and X.sub.2 being bound by a single bond to the ring when attached to H.sup.7 or H.sup.8 and by a double bond when not bound to H.sup.7 or H.sup.8, (c) H.sup.1-9 ; are hydrogens with the provision that H.sup.9 is only present when at least one of X.sub.1 and X.sub.2 is the NH.sup.9 group, (d) H.sup.7 and H.sup.8 are hydrogens that are attached to different atoms selected among X.sub.1, X.sub.2 and the nitrogen atom (N) in the quinoline ring, for the manufacture of a composition intended for inhibiting the production of tumor necrosis factor TNF in a living body and/or the treatment of septic shock in a living body.

Abstract: The present invention is related to the use of thiol-binding prostaglandins or prostaglandin-like substances containing alpha beta unsaturated ketone, esp. Prostaglandins of type A or J and derivatives or analogues thereof, for the preparation of ophthalmically compatible compositions for the prevention of cataracts.

Abstract: An injection cartridge is disclosed which has provision for the after injection of a rinsing solution to wash off the medicament that is first injected. The novel cartridge has a forward compartment and a rearward compartment, each having a piston disposed rearwardly thereof. A by-pass conduit is provided at the forward end of the cartridge which is longer than the thickness of the forwardmost piston. A medicament is positioned in the forward compartment and a rinsing solution is positioned in the rearward compartment. Moving the rearward piston forward forces the rinsing solution against the forward piston which in turn forces the medicament forward and expels it from the forward compartment. After the forward piston has reached its forward stop, the forward by-pass becomes open to the rearward compartment and continued forward movement of the rearward piston causes the rinsing solution to be forced through the forward by-pass and out the outlet end of the cartridge.

Abstract: A method of determining the affinity and kinetic properties of low molecular weight ligands for their interaction with a common receptor comprises the steps of immobilizing the receptor on a sensing structure, mixing in known proportions each ligand with a ligand analogue the response of which on the sensing structure is substantially higher than that of the low molecular weight ligands, contacting each mixture with the sensing structure and measuring the response, and comparing the response of each mixture with that of the ligand analogue alone, the distortion of the ligand analogue response being representative of the affinity and kinetic properties of the ligand.

Abstract: The present invention provides a pharmaceutical composition comprising an estramustine derivative and a cyclodextrin, particularly in the manufacture of a medicament suitable for the oral administration of an estramustine derivative to a patient suffering from a tumor.Estramustine derivatives according to the invention are, for example, compounds of general formula (I) ##STR1## wherein R is ##STR2## in which R.sub.1 is C.sub.1 -C.sub.4 alkyl and n is 0, 1 or 2, and the pharmaceutically acceptable salts thereof.

Abstract: The present invention concerns the use of Linomide.RTM. or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of retrovirus infections. Specifically the invention concerns the treatment of HIV infections.

Abstract: A 3,3-diphenylpropylamine of the formula I, or its physiologically acceptable acid salt thereof: ##STR1## wherein R.sup.1 represents hydrogen or methyl, R.sup.2 and R.sup.3 independently represent hydrogen, methyl, methoxy, hydroxy, carbamoyl, sulphamoyl or halogen, and X represents a tertiary amino group of formula II ##STR2## wherein R.sup.4 and R.sup.5 independently represent a hydroxy substituted or unsubstituted non-aromatic hydrocarbyl group which can join together to form a ring and which together contain at least three carbon atoms, wherein at least one of R.sup.4 and R.sup.5 is hydroxy substituted, is useful in treating acetylcholine-mediated disorders such as urinary incontinence.

Abstract: A method for smoking cessation therapy is described that utilizing an improved nicotine lozenge to satisfy transient craving. The lozenge contains nicotine, a nonnutritive sweetener and an absorbent excipient.

Abstract: A DNA sequence coding for a biologically active recombinant human factor VIII derivative, comprising a first DNA segment coding for the amino acids 1 through 740 of human factor VIII and a second DNA segment coding for the amino acids 1649 through 2332 of human factor VIII, said segments being interconnected by a linker DNA segment coding for a linker peptide of at least 3 amino acid residues and up to about 10 amino acid residues which are selected from lysine and arginine; recombinant expression vector comprising such DNA sequence; host cells of animal origin transformed with such recombinant expression vector; a process for the manufacture of recombinant human factor VIII derivative; and human factor VIII derivative containing the heavy chain and the light chain linked by metal ion bond.

Abstract: Novel compounds of the formula: ##STR1## wherein R is selected from saturated or unsaturated alkyls, saturated or unsaturated cycloalkyls, heterocyclic compounds, or from (a) or (b) wherein G is carbon wherein G is carbon or nitrogen; m is 0-10, wherein R.sub.1, R.sub.2, and R.sub.3 are the same or different and selected from hydrogen, halogen, alkyl having 1 to 5 carbon atoms, electron donor groups such as alkoxy having 1-5 carbons or hydroxy, electron acceptor groups selected from cyano, nitro, trifluoroalkyl and the pharmacologically acceptable salts thereof; being useful for treating disorder in the central nervous system.

Abstract: The present invention relates to the relief or prevention of withdrawal syndrome resulting from addiction to non-opiate type drugs of abuse and/or the suppression of dependence on non-opiate type drugs of abuse by administering to a person in need thereof, an effective amount of certain diphenylbutyl-piperazine-carboxamides including 4-[4,4-bis(4-fluorophenyl)butyl]-N-ethyl-1-piperazine-carboxamide which is known as amperozide.